Schering CEO Selection Being Closely Watched By Investors
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough's appointment of a new CEO, following the retirement of Richard Kogan later this month, could steady the firm's share price and help it weather what is expected to be a difficult year
You may also be interested in...
Pharmacia execs
CEO Fred Hassan advises Pfizer he will not join firm's Board of Directors as vice chairman, Pfizer announces April 14. With Federal Trade Commission approval of merger of Pharmacia with Pfizer occurring the same day, Hassan says he plans to "pursue other career opportunities" later this month. Hassan is said to be a front runner for the CEO post at Schering-Plough (1"The Tan Sheet" April 7, 2003, p. 10). Separately, Pharmacia R&D President Goran Ando will leave the company to serve as CEO for UK biotech firm Celltech...
Pharmacia execs
CEO Fred Hassan advises Pfizer he will not join firm's Board of Directors as vice chairman, Pfizer announces April 14. With Federal Trade Commission approval of merger of Pharmacia with Pfizer occurring the same day, Hassan says he plans to "pursue other career opportunities" later this month. Hassan is said to be a front runner for the CEO post at Schering-Plough (1"The Tan Sheet" April 7, 2003, p. 10). Separately, Pharmacia R&D President Goran Ando will leave the company to serve as CEO for UK biotech firm Celltech...
Pharmacia execs
CEO Fred Hassan advises Pfizer he will not join firm's Board of Directors as vice chairman, Pfizer announces April 14. With Federal Trade Commission approval of merger of Pharmacia with Pfizer occurring the same day, Hassan says he plans to "pursue other career opportunities" later this month. Hassan is said to be a front runner for the CEO post at Schering-Plough (1"The Tan Sheet" April 7, 2003, p. 10). Separately, Pharmacia R&D President Goran Ando will leave the company to serve as CEO for UK biotech firm Celltech...